NASDAQ:AMPH Amphastar Pharmaceuticals (AMPH) Stock Price, News & Analysis → Claim Your Complimentary Bitcoin Reward (From Crypto Swap Profits) (Ad) Free AMPH Stock Alerts $42.21 -0.22 (-0.52%) (As of 05/10/2024 ET) Add Compare Share Share Today's Range$41.26▼$42.8550-Day Range$38.65▼$47.3352-Week Range$38.43▼$67.66Volume595,849 shsAverage Volume336,097 shsMarket Capitalization$2.03 billionP/E Ratio14.61Dividend YieldN/APrice Target$66.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Amphastar Pharmaceuticals alerts: Email Address Amphastar Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside56.4% Upside$66.00 Price TargetShort InterestBearish11.35% of Float Sold ShortDividend StrengthN/ASustainability-2.21Upright™ Environmental ScoreNews Sentiment0.91Based on 19 Articles This WeekInsider TradingSelling Shares$655,145 Sold Last QuarterProj. Earnings Growth18.18%From $3.41 to $4.03 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.88 out of 5 starsMedical Sector40th out of 921 stocksPharmaceutical Preparations Industry15th out of 428 stocks 3.3 Analyst's Opinion Consensus RatingAmphastar Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 2 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageAmphastar Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.Read more about Amphastar Pharmaceuticals' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted11.35% of the float of Amphastar Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverAmphastar Pharmaceuticals has a short interest ratio ("days to cover") of 9.7.Change versus previous monthShort interest in Amphastar Pharmaceuticals has recently increased by 3.10%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldAmphastar Pharmaceuticals does not currently pay a dividend.Dividend GrowthAmphastar Pharmaceuticals does not have a long track record of dividend growth. Previous Next 3.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAmphastar Pharmaceuticals has received a 46.92% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Subcutaneous human immunoglobulin", "Procainamide", "Epinephrine", and "Medroxyprogesterone acetate" products. See details.Environmental SustainabilityThe Environmental Impact score for Amphastar Pharmaceuticals is -2.21. Previous Next 3.3 News and Social Media Coverage News SentimentAmphastar Pharmaceuticals has a news sentiment score of 0.91. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.53 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 19 news articles for Amphastar Pharmaceuticals this week, compared to 4 articles on an average week.Search InterestOnly 6 people have searched for AMPH on MarketBeat in the last 30 days. This is a decrease of -25% compared to the previous 30 days.MarketBeat Follows9 people have added Amphastar Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 80% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Amphastar Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $655,145.00 in company stock.Percentage Held by Insiders27.10% of the stock of Amphastar Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions65.09% of the stock of Amphastar Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Amphastar Pharmaceuticals' insider trading history. Previous Next 3.8 Earnings and Valuation Earnings GrowthEarnings for Amphastar Pharmaceuticals are expected to grow by 18.18% in the coming year, from $3.41 to $4.03 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Amphastar Pharmaceuticals is 14.61, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 126.38.Price to Earnings Ratio vs. SectorThe P/E ratio of Amphastar Pharmaceuticals is 14.61, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 105.49.Price to Earnings Growth RatioAmphastar Pharmaceuticals has a PEG Ratio of 1.02. PEG Ratios around 1 indicate that a company is correctly valued.Price to Book Value per Share RatioAmphastar Pharmaceuticals has a P/B Ratio of 3.02. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Amphastar Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Weiss Ratings[URGENT] DO NOT Touch These AI Stocks!Artificial intelligence stocks are carrying the market. One of them, Nvidia, recently became the seventh company ever to hit a $1 trillion market cap. But is this AI rally over?Click here for our #1 AI Stock for 2024 and Beyond About Amphastar Pharmaceuticals Stock (NASDAQ:AMPH)Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company provides Amphadase, an injection to absorb and disperse other injected drugs; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products; morphine injection for use with patient-controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges; Vasopressin to increase blood pressure; and Regadenoson, a stress agent for radionuclide myocardial perfusion imaging. Further, the company distributes recombinant human insulin APIs and porcine insulin API. Additionally, it develops generic product candidates, such as injectable, inhalation, and analytical technologies; biosimial product candidates; and intranasal epinephrine for the treatment of allergic reactions. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.Read More AMPH Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AMPH Stock News HeadlinesMay 3, 2024 | insidertrades.comAmphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Director Floyd F. Petersen Sells 500 SharesMay 10, 2024 | finance.yahoo.comAmphastar Pharmaceuticals Reports Strong First Quarter Earnings, Surpassing Analyst Revenue ...May 11, 2024 | Paradigm Press (Ad)Dems have chosen Biden replacement?On November 16, 2023… Joe Biden accidentally revealed the name of the candidate… Who will replace him in the 2024 presidential election.May 10, 2024 | finance.yahoo.comAmphastar Pharmaceuticals First Quarter 2024 Earnings: EPS: US$0.90 (vs US$0.54 in 1Q 2023)May 9, 2024 | finanznachrichten.deAmphastar Pharmaceuticals, Inc.: Amphastar Pharmaceuticals to Present at the Bank of America Securities Health Care ConferenceMay 9, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Amphastar Pharmaceuticals (AMPH) and Erasca (ERAS)May 9, 2024 | markets.businessinsider.comAmphastar Pharmaceuticals: Hold Rating Justified Amidst Growth Prospects and Pipeline PotentialMay 9, 2024 | insidermonkey.comAmphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Q1 2024 Earnings Call TranscriptMay 11, 2024 | Paradigm Press (Ad)Dems have chosen Biden replacement?On November 16, 2023… Joe Biden accidentally revealed the name of the candidate… Who will replace him in the 2024 presidential election.May 9, 2024 | finance.yahoo.comAmphastar Pharmaceuticals Inc (AMPH) Q1 2024 Earnings Call Transcript Highlights: Robust Growth ...May 9, 2024 | finance.yahoo.comQ1 2024 Amphastar Pharmaceuticals Inc Earnings CallMay 8, 2024 | investorplace.comAMPH Stock Earnings: Amphastar Pharma Beats EPS, Misses Revenue for Q1 2024May 8, 2024 | washingtonpost.comAmphastar: Q1 Earnings SnapshotMay 7, 2024 | markets.businessinsider.comWhat Wall Street expects from Amphastar Pharmaceuticals's earningsMay 4, 2024 | americanbankingnews.comFloyd F. Petersen Sells 500 Shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) StockMay 2, 2024 | americanbankingnews.comShort Interest in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Grows By 5.4%April 30, 2024 | finance.yahoo.comAmphastar Pharmaceuticals to Release First Quarter Earnings and Hold Conference Call on May 8, 2024April 30, 2024 | msn.comFTC Targets ‘Junk’ Patent Listings on Ozempic and Other DrugsApril 18, 2024 | markets.businessinsider.comAmphastar Pharmaceuticals Poised for Growth: Strong Generic Pipeline and Strategic Marketing Drive Buy RatingApril 16, 2024 | finance.yahoo.comNaloxone Market To Reach USD 2,478.6 Million By 2032 | DataHorizzon ResearchApril 12, 2024 | finance.yahoo.comAmphastar Pharmaceuticals (NASDAQ:AMPH) shareholders YoY returns are lagging the company's 66% three-year earnings growthApril 9, 2024 | msn.comAmphastar Pharmaceuticals (NASDAQ:AMPH) Offers Savvy Value Investors a Window of OpportunityApril 4, 2024 | msn.comAmphastar Pharmaceuticals (AMPH) Stock Moves -1%: What You Should KnowMarch 18, 2024 | markets.businessinsider.comAnalysts’ Top Healthcare Picks: Soleno Therapeutics (SLNO), Optinose (OPTN)March 16, 2024 | finance.yahoo.comAMPH Apr 2024 65.000 callMarch 16, 2024 | finance.yahoo.comAMPH Apr 2024 60.000 putMarch 9, 2024 | finance.yahoo.comAmphastar Pharmaceuticals Inc CFO, EVP & Treasurer William Peters Sells 18,136 SharesSee More Headlines Receive AMPH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Amphastar Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/28/2024Today5/11/2024Next Earnings (Estimated)8/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:AMPH CUSIPN/A CIK1297184 Webwww.amphastar.com Phone(909) 980-9484Fax909-980-8296Employees1,761Year FoundedN/APrice Target and Rating Average Stock Price Target$66.00 High Stock Price Target$71.00 Low Stock Price Target$60.00 Potential Upside/Downside+56.4%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)$2.89 Trailing P/E Ratio14.61 Forward P/E Ratio12.38 P/E Growth1.02Net Income$137.54 million Net Margins22.88% Pretax Margin27.46% Return on Equity29.17% Return on Assets12.11% Debt Debt-to-Equity Ratio0.88 Current Ratio2.18 Quick Ratio1.70 Sales & Book Value Annual Sales$644.40 million Price / Sales3.15 Cash Flow$4.34 per share Price / Cash Flow9.72 Book Value$13.98 per share Price / Book3.02Miscellaneous Outstanding Shares48,100,000Free Float35,062,000Market Cap$2.03 billion OptionableOptionable Beta0.85 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesDr. Ziping Luo Ph.D. (Age 74)Chairman of the Board, Chief Scientist & COO Comp: $1.53MDr. Yongfeng Zhang Ph.D. (Age 77)Co-Founder, President, CEO, Chief Scientific Officer & Director Comp: $2.13MMr. William J. Peters M.B.A. (Age 56)CFO, Executive VP of Finance, Treasurer & Director Comp: $1.12MMr. Jacob Liawatidewi M.B.A. (Age 50)Executive VP of Sales, Marketing & Corporate Administration Center, Corporate Secretary and Director Comp: $794.15kMr. Rong Zhou M.S. (Age 65)Senior Executive Vice President of Production Comp: $835.05kDan Dischner M.B.A.Vice President of Human Resources & Corporate CommunicationTony Marrs M.B.A.M.P.H., Senior VP of Regulatory Affairs & Clinical OperationsMore ExecutivesKey CompetitorsDeciphera PharmaceuticalsNASDAQ:DCPHAmneal PharmaceuticalsNASDAQ:AMRXKeros TherapeuticsNASDAQ:KROSRocket PharmaceuticalsNASDAQ:RCKTEdgewise TherapeuticsNASDAQ:EWTXView All CompetitorsInsiders & InstitutionsHillsdale Investment Management Inc.Sold 57,074 shares on 5/11/2024Ownership: 0.082%Cynosure Group LLCBought 7,254 shares on 5/11/2024Ownership: 0.015%Mark Sheptoff Financial Planning LLCSold 4,750 shares on 5/11/2024Ownership: 0.005%Vanguard Group Inc.Sold 81,556 shares on 5/10/2024Ownership: 5.685%State Board of Administration of Florida Retirement SystemSold 5,340 shares on 5/9/2024Ownership: 0.012%View All Insider TransactionsView All Institutional Transactions AMPH Stock Analysis - Frequently Asked Questions Should I buy or sell Amphastar Pharmaceuticals stock right now? 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Amphastar Pharmaceuticals in the last twelve months. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" AMPH shares. View AMPH analyst ratings or view top-rated stocks. What is Amphastar Pharmaceuticals' stock price target for 2024? 4 brokerages have issued twelve-month price objectives for Amphastar Pharmaceuticals' stock. Their AMPH share price targets range from $60.00 to $71.00. On average, they anticipate the company's stock price to reach $66.00 in the next year. This suggests a possible upside of 56.4% from the stock's current price. View analysts price targets for AMPH or view top-rated stocks among Wall Street analysts. How have AMPH shares performed in 2024? Amphastar Pharmaceuticals' stock was trading at $61.85 at the start of the year. Since then, AMPH shares have decreased by 31.8% and is now trading at $42.21. View the best growth stocks for 2024 here. When is Amphastar Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 13th 2024. View our AMPH earnings forecast. How were Amphastar Pharmaceuticals' earnings last quarter? Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) released its quarterly earnings results on Wednesday, February, 28th. The company reported $0.81 earnings per share for the quarter, missing analysts' consensus estimates of $0.84 by $0.03. The business had revenue of $178.11 million for the quarter, compared to analyst estimates of $174.90 million. Amphastar Pharmaceuticals had a trailing twelve-month return on equity of 29.17% and a net margin of 22.88%. What ETFs hold Amphastar Pharmaceuticals' stock? ETFs with the largest weight of Amphastar Pharmaceuticals (NASDAQ:AMPH) stock in their portfolio include Invesco Pharmaceuticals ETF (PJP), SPDR S&P Pharmaceuticals ETF (XPH), Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL), Janus Henderson Small Cap Growth Alpha ETF (JSML), ERShares NextGen Entrepreneurs ETF (ERSX), Invesco S&P SmallCap Health Care ETF (PSCH), iShares U.S. Pharmaceuticals ETF (IHE) and First Trust Active Factor Small Cap ETF (AFSM). What is Jack Y. Zhang's approval rating as Amphastar Pharmaceuticals' CEO? 35 employees have rated Amphastar Pharmaceuticals Chief Executive Officer Jack Y. Zhang on Glassdoor.com. Jack Y. Zhang has an approval rating of 35% among the company's employees. This puts Jack Y. Zhang in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. 48.0% of employees surveyed would recommend working at Amphastar Pharmaceuticals to a friend. What other stocks do shareholders of Amphastar Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Amphastar Pharmaceuticals investors own include Cara Therapeutics (CARA), Gilead Sciences (GILD), Amicus Therapeutics (FOLD), Exelixis (EXEL), CNX Resources (CNX), Immunomedics (IMMU), AbbVie (ABBV), Cellectis (CLLS), Clovis Oncology (CLVS) and Galectin Therapeutics (GALT). Who are Amphastar Pharmaceuticals' major shareholders? Amphastar Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (5.68%), Mesirow Institutional Investment Management Inc. (0.73%), Nordea Investment Management AB (0.68%), LSV Asset Management (0.47%), Principal Financial Group Inc. (0.45%) and Assenagon Asset Management S.A. (0.32%). Insiders that own company stock include Diane G Gerst, Floyd F Petersen, Howard Lee, Jack Y Zhang, Mary Z Luo, Michael A Zasloff, Richard K Prins, Richard Koo, Rong Zhou, William J Peters and Yakob Liawatidewi. View institutional ownership trends. How do I buy shares of Amphastar Pharmaceuticals? Shares of AMPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:AMPH) was last updated on 5/11/2024 by MarketBeat.com Staff From Our PartnersThe A.I. story nobody is telling you (Read ASAP)TradeSmithThe Crypto 9-5 Escape PlanCrypto 101 MediaDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeCollapse of the Petrodollar Colonial MetalsForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressHow Biden has already won 2024Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amphastar Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.